Antibodies against signal-regulatory protein alpha and methods of use
Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-α polypeptide. Also provided are polynucleotides, vectors, host cells, and methods of production and use related thereto.
1. An isolated antibody that binds an extracellular domain of a human SIRP-a polypeptide, wherein the antibody comprises:
(a) a heavy chain that comprises the amino acid sequence of SEQ ID NO:58, 62, or 124; and
(b) a light chain comprising a light chain variable (VL) domain that comprises the amino acid sequence of SEQ ID NO:25 or 40.
2. The antibody of claim 1 , wherein the light chain further comprises a lambda constant light chain (CL) domain that comprises the amino acid sequence of SEQ ID NO:37 or 46.
3. The antibody of claim 1 , wherein the light chain comprises the amino acid sequence of SEQ ID NO:47 or 55.
4. The antibody of claim 1 , wherein:
(a) the heavy chain comprises the amino acid sequence of SEQ ID NO:58, and the light chain comprises the amino acid sequence of SEQ ID NO:47;
(b) the heavy chain comprises the amino acid sequence of SEQ ID NO:62, and the light chain comprises the amino acid sequence of SEQ ID NO:47;
(c) the heavy chain comprises the amino acid sequence of SEQ ID NO:124, and the light chain comprises the amino acid sequence of SEQ ID NO:47;
(d) the heavy chain comprises the amino acid sequence of SEQ ID NO:58, and the light chain comprises the amino acid sequence of SEQ ID NO:55;
(e) the heavy chain comprises the amino acid sequence of SEQ ID NO:62, and the light chain comprises the amino acid sequence of SEQ ID NO:55; or
(f) the heavy chain comprises the amino acid sequence of SEQ ID NO:124, and the light chain comprises the amino acid sequence of SEQ ID NO:55.
5. The antibody of claim 1 , wherein the antibody enhances phagocytosis by a macrophage expressing a human SIRP-α polypeptide.
6. The antibody of claim 1 , wherein the antibody enhances activation of a dendritic cell expressing a human SIRP-α polypeptide.
7. The antibody of claim 1 , wherein the antibody inhibits in vivo growth of a tumor that expresses CD47.
8. A polynucleotide encoding the antibody of claim 1 .
9. A vector comprising the polynucleotide of claim 8 .
10. A host cell comprising the polynucleotide of claim 8 .
11. A method of producing an antibody, the method comprising culturing the host cell of claim 10 such that the antibody is produced.
12. The method of claim 11 , further comprising recovering the antibody from the host cell.
13. A method of treating or delaying progression of cancer in an individual, the method comprising administering to the individual an effective amount of the antibody of claim 1 .
14. The method of claim 13 , further comprising administering to the individual an effective amount of a second antibody that binds an antigen expressed by the cancer.
15. The method of claim 14 , wherein the antigen expressed by the cancer is selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD56, CD70, CD74, CD79b, CD123, CD138, CS1/SLAMF7, Trop-2, 5T4, EphA4, BCMA, PTK7, STEAP1, Endothelin B Receptor, mesothelin, ENPP3, SLC44A4, GNMB, nectin 4, NaPi2b, LIV-1A, Guanylyl cyclase C, DLL3, EGFR, HER2, VEGF, VEGFR, integrin αVβ3, integrin α 5 β1, MET, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, Tenascin, Leg, EpCAM, CEA, gpA33, PSMA, TAG72, a mucin, CAIX, EPHA3, folate receptor α, GD2, GD3, and an MHC/peptide complex comprising a peptide from NY-ESO-1/LAGE, SSX-2, a MAGE family protein, gp100/pme117, Melan-A/MART-1, gp75/TRP1, tyrosinase, TRP2, CEA, PSA, TAG-72, immature laminin receptor, MOK/RAGE-1, WT-1, SAP-1, BING-4, EpCAM, MUC1, PRAME, survivin, BRCA1, BRCA2, CDK4, CML66, MART-2, p53, Ras, β-catenin, TGF-βRII, HPV E6, or HPV E7.
16. The method of claim 13 , further comprising administering to the individual an effective amount of an immunotherapeutic agent.
17. The method of claim 16 , wherein the immunotherapeutic agent comprises a second antibody.
18. The method of claim 17 , wherein the second antibody binds to an antigen selected from the group consisting of BDCA2, BDCA4, ILT7, LILRB1, LILRB2, LILRB3, LILRB4, CSF-1R, CD40, CD40L, CD163, CD206, DEC205, CD47, CD123, IDO, TDO, 41BB, CTLA4, PD1, PD-L1, PD-L2, TIM-3, BTLA, VISTA, LAG-3, CD28, OX40, GITR, CD137, CD27, HVEM, CCR4, CD25, CD103, KIrg1, Nrp1, CD278, Gpr83, TIGIT, CD154, CD160, PVRIG, DNAM, and ICOS.
19. The method of claim 18 , wherein the second antibody binds to PD-1.
20. The method of claim 18 , wherein the second antibody binds to PD-L1.
21. The method of claim 16 , wherein the immunotherapeutic agent comprises a vaccine, oncolytic virus, adoptive cell therapy, cytokine, or small molecule agent.
22. The method of claim 15 , wherein the mucin is Mucin 1 or Mucin 16.
23. The method of claim 15 , wherein the EGFR is EGFRvIII.
24. The method of claim 15 , wherein the MAGE family protein is MAGE A3.